On March 13, 2024, Skye Bioscience, Inc. closed the transaction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.055 USD | +2.22% |
|
-13.38% | +184.38% |
06-24 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to S&P TMI Index | CI |
06-10 | Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+184.38% | 221M | |
+26.52% | 52.73B | |
+37.49% | 39B | |
-9.23% | 38.52B | |
+29.46% | 30.38B | |
-12.26% | 26.39B | |
+10.72% | 26.08B | |
+45.15% | 14.15B | |
+32.36% | 12.6B | |
-5.99% | 11.51B |
- Stock Market
- Equities
- EMBI Stock
- News Skye Bioscience, Inc.
- Skye Bioscience, Inc. announced that it has received $40 million in funding